title: Administration of heparin by subcutaneous infusion with a programmable pump.
abstract: Heparin has a short half-life (8 to 12 hours) and therefore must be administered by continuous infusion or by intermittent subcutaneous injection. Intermittent subcutaneous injection may lead to fluctuation in the levels of anticoagulation attained. In correcting this deficiency, the programmable automated subcutaneous infusion pump in conjunction with weekly home nursing visits has been used. Eight pregnant women with documented deep venous thrombosis or embolic events before pregnancy who received such therapy were studied. Eight similar subjects who received intermittent subcutaneous injection, matched for age, parity, site of deep venous thrombosis, and days on a regimen of heparin therapy, served as the control group. The mean daily dose of heparin by subcutaneous infusion pump was higher (29,445 vs 13,822 U), resulting in smoother, more therapeutic heparinization (mean partial thromboplastin time, 20.6 vs 10.4 seconds above control) when compared with the intermittent subcutaneous injection group (p less than 0.05, p less than 0.007). There were two complications (hematoma, site infection) in the intermittent subcutaneous injection group while none occurred in the subcutaneous infusion pump group. When used in concert with weekly home visits, the subcutaneous infusion pump method of administration allowed more even control of anticoagulation, appeared to result in fewer complications (although not statistically significant), and subjectively was better received by patients than the intermittent subcutaneous injection technique.
authors.affiliation: Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505.
authors.forename: R C
authors.initials: RC
authors.lastname: Floyd
authors.forename: K S
authors.initials: KS
authors.lastname: Gookin
authors.forename: L W
authors.initials: LW
authors.lastname: Hess
authors.forename: R W
authors.initials: RW
authors.lastname: Martin
authors.forename: K F
authors.initials: KF
authors.lastname: Rawlinson
authors.forename: R K
authors.initials: RK
authors.lastname: Moenning
authors.forename: J C
authors.initials: JC
authors.lastname: Morrison
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D015918:Infusion Pumps, Implantable; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D012189:Retrospective Studies; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D006493:Heparin